Attrition after Neoadjuvant Chemotherapy in Foregut Cancer: Experience at a Tertiary Center in the Deep South.

IF 3.5 2区 医学 Q2 ONCOLOGY
Annals of Surgical Oncology Pub Date : 2025-10-01 Epub Date: 2025-07-17 DOI:10.1245/s10434-025-17795-8
Michelle Holland, Jaspinder Sanghera, Ioannis Liapis, Rida Ahmad, Krisha Amin, Ahmed Abdalla, Martin J Heslin, Smita Bhatia, Annabelle L Fonseca
{"title":"Attrition after Neoadjuvant Chemotherapy in Foregut Cancer: Experience at a Tertiary Center in the Deep South.","authors":"Michelle Holland, Jaspinder Sanghera, Ioannis Liapis, Rida Ahmad, Krisha Amin, Ahmed Abdalla, Martin J Heslin, Smita Bhatia, Annabelle L Fonseca","doi":"10.1245/s10434-025-17795-8","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Neoadjuvant chemotherapy (NAC) is increasingly used in the management of foregut cancers to downstage tumors, treat micrometastases, and improve oncological outcomes. However, many patients fail to undergo surgical resection after NAC. This study aims to identify the underlying causes of non-tumor biology-related attrition and thus evaluate the potentially modifiable factors contributing to pre-surgical attrition.</p><p><strong>Methods: </strong>A retrospective review was conducted of patients with non-metastatic gastric or pancreatic adenocarcinoma treated between 2018-2022 at a tertiary and safety net hospital in the Southeastern U.S. Multivariable logistic regression and a root cause analysis (RCA) were performed to examine the association of sociodemographic factors with attrition and delineate underlying root causes.</p><p><strong>Results: </strong>Of 169 patients who received NAC, 47% (n = 80) experienced potentially modifiable attrition that was unrelated to disease progression. A diagnosis of pancreatic cancer (p = 0.001), age ≥ 75 (p = 0.04), and ≥ 3 ED visits after diagnosis (p=0.03) were independently associated with attrition on multivariable analysis. Four causes of non-tumor biology-related attrition were identified on RCA: physical deconditioning due to chemotherapy toxicity, malignancy or procedural complications, loss to follow-up resulting from missed appointments, healthcare delivery factors including delayed or absent referral to specialists, and patient refusal of treatment. Attrition was associated with significantly worse survival in both pancreatic and gastric cancer.</p><p><strong>Discussion: </strong>Nearly 50% of patients receiving NAC for pancreatic and gastric cancer failed to undergo surgery due to potentially modifiable causes. Addressing the underlying barriers through the implementation of structured prehabilitation programs, symptom management clinics, and cancer care navigators may reduce non-tumor biology-related attrition and improve outcomes.</p>","PeriodicalId":8229,"journal":{"name":"Annals of Surgical Oncology","volume":" ","pages":"7740-7750"},"PeriodicalIF":3.5000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12454533/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Surgical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1245/s10434-025-17795-8","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/17 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Neoadjuvant chemotherapy (NAC) is increasingly used in the management of foregut cancers to downstage tumors, treat micrometastases, and improve oncological outcomes. However, many patients fail to undergo surgical resection after NAC. This study aims to identify the underlying causes of non-tumor biology-related attrition and thus evaluate the potentially modifiable factors contributing to pre-surgical attrition.

Methods: A retrospective review was conducted of patients with non-metastatic gastric or pancreatic adenocarcinoma treated between 2018-2022 at a tertiary and safety net hospital in the Southeastern U.S. Multivariable logistic regression and a root cause analysis (RCA) were performed to examine the association of sociodemographic factors with attrition and delineate underlying root causes.

Results: Of 169 patients who received NAC, 47% (n = 80) experienced potentially modifiable attrition that was unrelated to disease progression. A diagnosis of pancreatic cancer (p = 0.001), age ≥ 75 (p = 0.04), and ≥ 3 ED visits after diagnosis (p=0.03) were independently associated with attrition on multivariable analysis. Four causes of non-tumor biology-related attrition were identified on RCA: physical deconditioning due to chemotherapy toxicity, malignancy or procedural complications, loss to follow-up resulting from missed appointments, healthcare delivery factors including delayed or absent referral to specialists, and patient refusal of treatment. Attrition was associated with significantly worse survival in both pancreatic and gastric cancer.

Discussion: Nearly 50% of patients receiving NAC for pancreatic and gastric cancer failed to undergo surgery due to potentially modifiable causes. Addressing the underlying barriers through the implementation of structured prehabilitation programs, symptom management clinics, and cancer care navigators may reduce non-tumor biology-related attrition and improve outcomes.

前肠癌新辅助化疗后的耗损:在美国南方腹地三级中心的经验。
背景:新辅助化疗(NAC)越来越多地用于前肠癌的治疗,以降低肿瘤分期,治疗微转移,改善肿瘤预后。然而,许多患者在NAC后未能进行手术切除。本研究旨在确定非肿瘤生物学相关磨损的潜在原因,从而评估导致术前磨损的潜在可改变因素。方法:回顾性分析2018-2022年间在美国东南部一家三级医院和安全网医院接受治疗的非转移性胃或胰腺腺癌患者,采用多变量logistic回归和根本原因分析(RCA)来检查社会人口因素与磨蚀的关系,并描述潜在的根本原因。结果:169名接受NAC治疗的患者中,47% (n = 80)经历了与疾病进展无关的潜在可改变的磨损。多变量分析显示,胰腺癌诊断(p= 0.001)、年龄≥75岁(p= 0.04)、诊断后ED就诊≥3次(p=0.03)与损耗独立相关。在RCA上确定了非肿瘤生物学相关损耗的四个原因:化疗毒性导致的身体机能丧失、恶性肿瘤或手术并发症、错过预约导致的随访损失、医疗保健提供因素(包括延迟或没有转诊到专科医生)和患者拒绝治疗。在胰腺癌和胃癌中,磨损与较差的生存率显著相关。讨论:近50%接受NAC治疗的胰腺癌和胃癌患者由于潜在的可改变的原因未能进行手术。通过实施结构化的康复计划、症状管理诊所和癌症护理导导员来解决潜在的障碍,可能会减少非肿瘤生物学相关的损耗并改善结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.90
自引率
10.80%
发文量
1698
审稿时长
2.8 months
期刊介绍: The Annals of Surgical Oncology is the official journal of The Society of Surgical Oncology and is published for the Society by Springer. The Annals publishes original and educational manuscripts about oncology for surgeons from all specialities in academic and community settings.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信